Lexeo Acquires Mantle for $8.3 Million to Expand Friedreich Ataxia Pipeline

Deal adds oral and brain-targeted FA treatments to Lexeo’s pipeline. LX2006 gene therapy stays top priority, with pivotal data due in late 2027.